Resource Development for Duchenne and Becker Muscular Dystrophies
(CDLink Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on gathering crucial information to advance research on Duchenne and Becker muscular dystrophies (DMD/BMD). It aims to collect data from individuals diagnosed with these conditions or who are carriers, to enhance understanding and eventually develop treatments. Anyone over four weeks old with a confirmed diagnosis of DMD/BMD or who is a carrier can participate. This trial does not test any treatments but instead creates a resource for future research. As an unphased trial, participation helps build a vital resource that could lead to breakthroughs in understanding and treating these conditions.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
Why are researchers excited about this trial?
Researchers are excited about the CureDuchenne Link® trial because it aims to create a valuable resource for research on Duchenne muscular dystrophy (DMD). Unlike traditional treatments that focus on slowing disease progression or managing symptoms, this initiative seeks to gather comprehensive data that could accelerate the development of new therapies. By building a robust database, researchers hope to identify novel targets for treatment, enhance understanding of the disease, and ultimately lead to breakthroughs that current options, like steroids or physical therapy, haven't achieved. This approach has the potential to transform how we understand and tackle DMD in the future.
Who Is on the Research Team?
Debra Miller
Principal Investigator
CureDuchenne
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
Participants provide documentation to support their diagnosis and genetic mutation status
Long-term Monitoring
Participants' health and functional status are monitored every 6-12 months for up to ten years
Follow-up
Participants are monitored for safety and effectiveness after data collection
What Are the Treatments Tested in This Trial?
Interventions
- None
Find a Clinic Near You
Who Is Running the Clinical Trial?
CureDuchenne
Lead Sponsor